Press Releases

Date Title  
Toggle Summary Natera Reports Third Quarter 2015 Financial Results
SAN CARLOS, Calif. , Nov. 12,  2015 /PRNewswire/ --  Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis  of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2015 and provided an update on recent business
Toggle Summary LifeLabs Now Offering Panorama™ NIPT in Canada via Natera's Constellation Software Platform
Constellation™ software provides access to Natera's innovative bioinformatics through the cloud SAN CARLOS, Calif. , Nov. 3, 2015 /PRNewswire/ --  Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that LifeLabs
Toggle Summary Natera to Release Third Quarter 2015 Results on November 12, 2015
SAN CARLOS, Calif. , Oct. 30, 2015 /PRNewswire/ --  Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 2015 after the market close on November 12,
Toggle Summary Natera Study Demonstrates Performance of mmPCR Technology in Identifying Breast Cancer
mmPCR can accurately detect CNVs with approximately 5 times higher sensitivity than existing methods First published report demonstrating detection of subclonal mutations in plasma that may be missed in tumor tissue biopsies SAN CARLOS, Calif. , Oct. 28, 2015 /PRNewswire/ -- Natera, Inc., ( NTRA ),
Toggle Summary Natera to Present at ASRM Annual Meeting
SAN CARLOS, Calif. , Oct. 16, 2015 /PRNewswire/ -- Natera, Inc., ( NTRA ), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of reproductive genetic tests and screens will be highlighted during
Toggle Summary Natera to Present at ASHG Annual Scientific Conference
SAN CARLOS, Calif. , Oct. 6, 2015 /PRNewswire/ -- Natera, Inc. , (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of genetic testing products will be highlighted during three
Toggle Summary Natera Reports Second Quarter 2015 Financial Results
SAN CARLOS, Calif. , Aug. 12, 2015 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2015 and provided an update on recent business progress.
Toggle Summary Recent Publication Supports the Cost Effectiveness of NIPT for All Pregnant Women, Regardless of Prior Risk
SAN CARLOS, Calif. , Aug. 10, 2015 /PRNewswire/ -- Natera, Inc. , (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced new data that supports the use of non-invasive prenatal testing (NIPT) as a first line screening for chromosomal
Toggle Summary Natera to Release Second Quarter 2015 Results on August 12, 2015
SAN CARLOS, Calif. , Aug. 4, 2015 /PRNewswire/ --  Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, 2015 after the market close on August 12, 2015 .
Toggle Summary Natera Selected for NHS-Funded TRACERx Study of Lung Cancer Heterogeneity Using Cell-Free Tumor DNA
-- Natera's proprietary mmPCR technology to provide high sensitivity for blood-based detection of elusive subclonal tumor variations -- SAN CARLOS, Calif. , July 8, 2015 / PRNewswire / -- Natera, Inc., a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.